Our results showed that levels of phosphorylated GSK were increased in papillary and anaplastic thyroid cancer cells overexpressing BRAF V600E (Figures 6C,D and 7F). This evidence concerns the gene BRAF and thyroid gland undifferentiated (anaplastic) carcinoma.